Aktienanalyse zu Climb Bio Inc (CLYM)CLYMClimb Bio Inc

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy. It operates in the Healthcare sector.

Climb Bio Inc is currently a hold. The stock has a current price of $9.82, with a significant year-to-date change of +161.87%, but it has recently dropped by 10.73% over the past five days. The RSI is at 27.546, indicating that the stock is oversold, which could suggest a potential rebound. However, the company continues to report negative earnings, with a forward P/E ratio of 0 and a net income loss of $13.72 million in Q1 2026. The main risk is the ongoing financial losses, which could impact investor confidence.